Stocks / NASDAQ / Boundless Bio Inc.

Boundless Bio Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: BOLD – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Boundless Bio Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in the following report that they exploit animals for product testing.

“In this model where amplification-mediated resistance to KRAS^G12C inhibitor treatment was already established, BBI-825 significantly inhibited tumor growth as monotherapy, showing 92% tumor growth inhibition compared to vehicle or adagrasib alone, including tumor regressions in multiple animals.” (Page 144) Read the full document

Company Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company’s lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Company Website: https://www.boundlessbio.com

Contact: renee@thrustsc.com